BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 36969744)

  • 1. Under-Representation of Racial Groups in Genomics Studies of Gastroenteropancreatic Neuroendocrine Neoplasms.
    Herring BR; Bonner A; Guenter RE; Vickers S; Yates C; Lee G; Dhall D; Chen H; Rose JB
    Cancer Res Commun; 2022 Oct; 2(10):1162-1173. PubMed ID: 36969744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).
    Puccini A; Poorman K; Salem ME; Soldato D; Seeber A; Goldberg RM; Shields AF; Xiu J; Battaglin F; Berger MD; Tokunaga R; Naseem M; Barzi A; Iqbal S; Zhang W; Soni S; Hwang JJ; Philip PA; Sciallero S; Korn WM; Marshall JL; Lenz HJ
    Clin Cancer Res; 2020 Nov; 26(22):5943-5951. PubMed ID: 32883742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study.
    Feola T; Puliani G; Sesti F; Modica R; Centello R; Minotta R; Cannavale G; Di Meglio S; Di Vito V; Lauretta R; Appetecchia M; Colao A; Lenzi A; Isidori AM; Faggiano A; Giannetta E
    J Endocrinol Invest; 2022 Apr; 45(4):849-857. PubMed ID: 35040099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of sequence polymorphisms in the displacement loop region of mitochondrial DNA as a risk factor for gastroenteropancreatic neuroendocrine neoplasm.
    Er LM; Wu ML; Gao Y; Wang SJ; Li Y
    J Clin Lab Anal; 2017 Sep; 31(5):. PubMed ID: 27704598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions.
    Detjen K; Hammerich L; Özdirik B; Demir M; Wiedenmann B; Tacke F; Jann H; Roderburg C
    Neuroendocrinology; 2021; 111(3):217-236. PubMed ID: 32615560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Venizelos A; Sorbye H; Elvebakken H; Perren A; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Vestermark LW; Ladekarl M; Tabaksblat EM; Knappskog S
    Endocr Relat Cancer; 2023 Oct; 30(10):. PubMed ID: 37410378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia.
    Dizdar L; Oesterwind KA; Riemer JC; Werner TA; Mersch S; Möhlendick B; Schütte SC; Verde PE; Raba K; Topp SA; Stoecklein NH; Esposito I; Knoefel WT; Krieg A
    Oncotarget; 2017 Jan; 8(5):8369-8382. PubMed ID: 28039474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models.
    Kawasaki K; Fujii M; Sato T
    Dis Model Mech; 2018 Feb; 11(2):. PubMed ID: 29590641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?
    Fazio N; La Salvia A
    Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101794. PubMed ID: 37414651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm.
    Wang Y; Chen Y; Li X; Hu W; Zhang Y; Chen L; Chen M; Chen J
    BMC Cancer; 2018 Jun; 18(1):691. PubMed ID: 29940892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid-derived suppressor cells in gastroenteropancreatic neuroendocrine neoplasms.
    Liu M; Zhang Y; Chen L; Lin Y; He Q; Zeng Y; Chen M; Chen J
    Endocrine; 2021 Jan; 71(1):242-252. PubMed ID: 33010002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy.
    Viol F; Sipos B; Fahl M; Clauditz TS; Amin T; Kriegs M; Nieser M; Izbicki JR; Huber S; Lohse AW; Schrader J
    Cell Oncol (Dordr); 2022 Dec; 45(6):1401-1419. PubMed ID: 36269546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF
    Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
    Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping.
    Kawasaki K; Toshimitsu K; Matano M; Fujita M; Fujii M; Togasaki K; Ebisudani T; Shimokawa M; Takano A; Takahashi S; Ohta Y; Nanki K; Igarashi R; Ishimaru K; Ishida H; Sukawa Y; Sugimoto S; Saito Y; Maejima K; Sasagawa S; Lee H; Kim HG; Ha K; Hamamoto J; Fukunaga K; Maekawa A; Tanabe M; Ishihara S; Hamamoto Y; Yasuda H; Sekine S; Kudo A; Kitagawa Y; Kanai T; Nakagawa H; Sato T
    Cell; 2020 Nov; 183(5):1420-1435.e21. PubMed ID: 33159857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update.
    Kole C; Charalampakis N; Vailas M; Tolia M; Sotiropoulou M; Tsakatikas S; Kouris NI; Tsoli M; Koumarianou A; Karamouzis MV; Schizas D
    Cancer Immunol Immunother; 2022 Apr; 71(4):761-768. PubMed ID: 34471940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant Expression of Long Non Coding RNA HOTAIR and De-Regulation of the Paralogous 13 HOX Genes Are Strongly Associated with Aggressive Behavior of Gastro-Entero-Pancreatic Neuroendocrine Tumors.
    Di Mauro A; Scognamiglio G; Aquino G; Cerrone M; Liguori G; Clemente O; Di Bonito M; Cantile M; Botti G; Tafuto S; Tatangelo F
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34208964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
    Zanini S; Renzi S; Giovinazzo F; Bermano G
    Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
    Masui T; Ito T; Komoto I; Uemoto S;
    BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs.
    Shi M; Fan Z; Xu J; Yang J; Li Y; Gao C; Su P; Wang X; Zhan H
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188637. PubMed ID: 34678439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.